Effects of NMDA receptor antagonists on morphine tolerance: A c-Fos study in the lumbar spinal cord of the rat

European Journal of Pharmacology

Volumn 373, Issue 1, 1999, Pages 1-11

  Le Guen, Stéphanie ^a   Catheline, Gwénaëlle ^a   Besson, Jean Marie ^a  

^a PSL RESEARCH UNIVERSITY   (France)

Author keywords

c Fos; Inflammation; Morphine; NMDA receptor antagonist; Spinal cord; Tolerance

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; CARRAGEENAN; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PROTEIN C FOS;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LUMBAR SPINAL CORD; MALE; MORPHINE TOLERANCE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; SPINAL CORD DORSAL HORN; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESICS, OPIOID; ANIMALS; BINDING SITES; CARRAGEENAN; DIZOCILPINE MALEATE; DRUG TOLERANCE; EXCITATORY AMINO ACID ANTAGONISTS; GLYCINE; IMMUNOHISTOCHEMISTRY; ISOQUINOLINES; MALE; MORPHINE; NEURONS; PROTO-ONCOGENE PROTEINS C-FOS; PYRROLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SPINAL CORD;

EID: 0033029220     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00272-1     Document Type: Article

References (67)

1. Abbadie, C., Honoré, P., Besson, J.-M., 1994a. Postsynaptic changes during sustained primary afferent fiber stimulation as revealed by c-Fos immunohistochemistry in the rat spinal cord. In: Laszlo Urban (Ed.), NATO ASI Series, Vol. H 79. Cellular mechanisms of sensory processing. Springer-Verlag, Berlin Heidelberg, pp. 449-471.
2. Abbadie C., Honoré P., Fournié-Zaluski M.-C., Roques B.P., Besson J.-M. Effects of opioids and non-opioids on c-Fos immunoreactivity induced in rat lumbar spinal cord neurons by noxious heat stimulation. Eur. J. Pharmacol. 258:1994;215-227.
3. Bell J.A., Beglan C.L. Co-treatment with MK-801 potentiates naloxone-precipitated morphine withdrawal in the isolated spinal cord of the neonatal rat. Eur. J. Pharmacol. 294:1995;297-301.
4. Bell J.A., Beglan C.L. MK-801 blocks the expression but not the development of tolerance to morphine in the isolated spinal cord of the neonatal rat. Eur. J. Pharmacol. 294:1995;289-296.
5. Ben-Eliyahu S., Marek P., Vaccarino A.L., Mogil J.S., Sternberg W.F., Liebeskind J.C. The NMDA receptor antagonist MK-801 prevents long-lasting non-associative morphine tolerance in the rat. Brain Res. 575:1992;304-308.
6. Besson J.-M., Chaouch A. Peripheral and spinal mechanisms of nociception. Physiol. Rev. 67:1987;67-186.
7. Bhargava H.N. Diversity of agents that modify opioid tolerance, physical dependence, abstinence syndrome, and self-administrative behavior. Pharmacol. Rev. 46(3):1994;293-324.
8. Bhargava H.N. Enhancement of morphine actions in morphine-naive and morphine-tolerant mice by LY 235959, a competitive antagonist of the NMDA receptor. Gen. Pharmacol. 28(1):1997;61-64.
9. Bhargava H.N., Matwyshyn G.A. Dizocilpine (MK-801) blocks tolerance to the analgesic but not to the hyperthermic effect of morphine in the rat. Pharmacology. 47:1993;344-350.
10. Bhargava H.N., Thorat S.N. Differential effects of LY235959, a competitive antagonist of the NMDA receptor on k-opioid receptor agonist induced responses in mice and rats. Brain Res. 747:1997;246-251.
11. Bilsky E.J., Inturrisi C.E., Sadée W., Hruby V.J., Porreca F. Competitive and non-competitive NMDA antagonists block the development of antinociceptive tolerance to morphine, but not to selective μ or δ opioid agonists in mice. Pain. 68:1996;229-237.
12. Bristow L.J., Hogg J.E., Hutson P.H. Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Neuropharmacology. 36(2):1997;241-250.
13. Bullitt E., Lee C.L., Light A.R., Willcockson H.H. The effect of stimulus duration on noxious-stimulus induced c-fos expression in the rodent spinal cord. Brain Res. 580:1992;170-172.
14. Chapman, V., Besson, J.-M., 1997. Pharmacological studies of nociceptive systems using the c-Fos immunohistochemical technique: an indicator of noxiously activated spinal neurones. In: Dickenson, A.H., Besson, J.-M. (Eds.), Handbook of Experimental Pharmacology: The Pharmacology of Pain. Springer-Verlag, Berlin, pp. 235-279.
15. Chapman V., Honoré P., Buritova J., Besson J.-M. The contribution of NMDA receptor activation to spinal c-Fos expression in a model of inflammatory pain. Br. J. Pharmacol. 116:1995;1628-1634.
16. Coggeshall R.E., Carlton S.M. Receptor localization in the mammalian dorsal horn and primary afferent neurons. Brain Res. Rev. 24:1997;28-66.
17. Collier H.O.J., Francis D.L., Schneider C. Modification of morphine withdrawal by drugs interacting with humoral mechanisms: some contradictions and their interpretation. Nature. 237:1972;220-223.
18. Dickenson, A.H., 1994. NMDA receptor antagonists as analgesics. In: Fields, H.L., Liebeskind, J.C. (Eds.), Progress in Pain Research and Management. IASP Press, Seattle, pp. 173-187.
19. Dickenson A.H., Chapman V., Green G.M. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen. Pharmacol. 28(5):1997;633-638.
20. Draisci G., Iadarola M.J. Temporal analysis of increases in c-fos, preprodynorphin and preproenkephalin mRNAs in rat spinal cord. Mol. Brain Res. 6:1989;31-37.
21. Dunbar S.A., Yaksh T.L. Concurrent spinal infusion of MK801 blocks spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Anesthesiology. 84:1996;1177-1188.
22. Elliott K.J., Hynansky A.D., Inturrisi C.E. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain. 59:1994;361-368.
23. G-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain. 56:1994;69-75.
24. Elliott K.J., Kest B., Man A., Kao B., Inturrisi C.E. N-Methyl-D-aspartate (NMDA) receptors, mu and kappa opioid tolerance, and perspectives on new analgesic drug development. Neuropsychopharmacology. 13:1995;347-356.
25. Feng J.Q., Kendig J.J. The NMDA receptor antagonist MK-801 differentially modulates mu and kappa opioid actions in spinal cord in vitro. Pain. 66:1996;343-349.
26. Frederickson R.C.A., Smits S.E. Time course of dependence and tolerance development in rats treated with 'slow release' morphine suspensions. Res. Commun. Chem. Pathol. Pharmacol. 5:1973;867-870.
27. Gonzalez P., Cabello P., Germany A., Norris B., Contreras E. Decrease of tolerance to, and physical dependence on morphine by, glutamate receptor antagonists. Eur. J. Pharmacol. 332(3):1997;257-262.
28. Gutstein H.B., Trujillo K.A. MK-801 inhibits the development of morphine tolerance at spinal sites. Brain Res. 626:1993;332-334.
29. Haberny K.A., Young G.A. Interactive effects of MK-801 and morphine on EEG, EEG power spectra and behavior in rats: I. Morphine tolerance development. Eur. J. Pharmacol. 261:1994;1-9.
30. Herman B.H., Vocci F., Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology. 13:1995;269-293.
31. Hoffmann O., Wiesenfeld-Hallin Z. Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats. NeuroReport. 7:1996;838-840.
32. Honoré P., Buritova J., Besson J.-M. Carrageenin-evoked c-Fos expression in rat lumbar spinal cord: the effects of indomethacin. Eur. J. Pharmacol. 272:1995;249-259.
33. Honoré P., Chapman V., Buritova J., Besson J.-M. When is the maximal effect of pre-administered systemic morphine on carrageenin-evoked spinal c-Fos expression in the rat? Brain Res. 705:1995;91-96.
34. Honoré P., Buritova J., Besson J.-M. The effects of morphine on carrageenin-induced spinal c-Fos expression are completely blocked by β-funaltrexamine, a selective mu opioid receptor antagonist. Brain Res. 732:1996;242-246.
35. Honoré P., Catheline G., Le Guen S., Besson J.-M. Chronic treatment with systemic morphine induced tolerance to the systemic and peripheral antinociceptive effects of morphine on both carrageenin induced mechanical hyperalgesia and spinal c-Fos expression in awake rats. Pain. 71:1997;99-108.
36. Hsu S., Raine L., Fanger H. Use of avidin-biotin-peroxydase complex (ABC) in immunoperoxydase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J. Histochem. Cytochem. 29:1981;577-580.
37. Ibuki T., Dunbar S.A., Yaksh T.L. Effect of transient naloxone antagonism on tolerance development in rats receiving continuous spinal morphine infusion. Pain. 70:1997;125-132.
38. Inturrisi C.E. Preclinical evidence for a role of glutamatergic systems in opioid tolerance and dependence. Semin. Neurosci. 9(3-4):1997;110-119.
39. Inturrisi C.E., Shimoyama N., Shimoyama M., Foley K.M., Elliott K.J. NMDA-R1 antisense attenuates morphine tolerance. Soc. Neurosci. 22:1996;1760. Part 3.
40. Kolesnikov Y.A., Maccechini M.-L., Pasternak G.W. 1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 55:1994;1393-1398.
41. Le Guen, S., Catheline, G., Lombard, M.-C., Besson, J.-M., 1997. Moderate effects of a NMDA receptor antagonist on morphine tolerance: a c-Fos study in the spinal cord of the rat. Soc. Neurosci. 23-70.5, 162.
42. Lutfy K., Shen K.-Z., Kwon I.-K., Cai S.X., Woodward R.M., Keana J.F.W., Weber E. Blockade of morphine tolerance by ACEA-1328, a novel NMDA receptor/glycine site antagonist. Eur. J. Pharmacol. 273:1995;187-189.
43. Lutfy K., Shen K.-F., Woodward R.M., Weber E. Inhibition of morphine tolerance by NMDA receptor antagonists in the formalin test. Brain Res. 731:1996;171-181.
44. Manning B.H., Mao J.R., Frenk H., Price D.D., Mayer D.J. Continuous co-administration of dextromethorphan or MK-801 with morphine: attenuation of morphine dependence and naloxone-reversible attenuation of morphine tolerance. Pain. 67:1996;79-88.
45. Mao J.R., Price D.D., Mayer D.J. Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J. Neurosci. 14:1994;2301-2312.
46. Mao J.R., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 62:1995;259-274.
47. Mao J.R., Price D.D., Caruso F.S., Mayer D.J. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain. 67:1996;361-368.
48. Mao J.R., Price D.D., Lu J., Mayer D.J. Antinociceptive tolerance to the mu-opioid agonist DAMGO is dose-dependently reduced by MK-801 in rats. Neurosci. Lett. 250(3):1998;193-196.
49. Marek P., Ben-Eliyahu S., Vaccarino A.L., Liebeskind J.C. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res. 558:1991;163-165.
50. Martin J.L., Magistretti P.J. Regulation of gene expression by neurotransmitters in the central nervous system. Eur. Neurol. 39(3):1998;129-134.
51. Molander C., Xu Q., Grant G. The cytoarchitectonic organization of the spinal cord in the rat: I. The lower thoracic and lumbosacral cord. J. Comp. Neurol. 230:1984;133-141.
52. Noguchi K., Kowalski K., Traub R.J., Solodkin A., Iadarola M.J., Ruda M.A. Dynorphin expression and Fos-like immunoreactivity following inflammation induced hyperalgesia are colocalized in spinal cord neurons. Mol. Brain Res. 10:1991;227-233.
53. Noguchi K., Dubner R., Ruda M.A. Preproenkephalin mRNA in spinal dorsal horn neurons is induced by peripheral inflammation and is co-localized with Fos and Fos-related proteins. Neuroscience. 46:1992;561-570.
54. Reynolds I.J. Modulation of NMDA receptor responsiveness by neurotransmitters, drugs and chemical modification. Life Sci. 47:1990;1785-1792.
55. Robichon R., Randall P.K., Leslie S.W. A partial agonist model used in the allosteric modulation of the NMDA receptor. Eur. J. Pharmacol. 328:1997;255-263.
56. Rohde D.S., Detweiler D.J., Basbaum A.I. Formalin-evoked Fos expression in spinal cord is enhanced in morphine-tolerant rats. Brain Res. 766:1997;93-100.
57. Shimoyama N., Shimoyama M., Inturrisi C.E., Elliott K.J. Ketamine attenuates and reverses morphine tolerance in rodents. Anesthesiology. 85:1996;1357-1366.
58. Su M.T., Lin W.B., Lue W.M., Cheng C.Y., Tao P.-L. Blockade of the development of morphine tolerance by U-50,488, an AVP antagonist or MK-801 in the rat hippocampal slice. Br. J. Pharmacol. 123(4):1998;625-630.
59. Tiseo P.J., Inturrisi C.E. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist, LY274614. J. Pharmacol. Exp. Ther. 264:1993;1090-1096.
60. Tiseo P.J., Cheng J., Pasternak G.W., Inturrisi C.E. Modulation of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY274614: assessment of opioid receptor changes. J. Pharmacol. Exp. Ther. 268(1):1994;195-201.
61. Trujillo K.A. Effects of noncompetitive N-methyl-D-aspartate receptor antagonists on opiate tolerance and physical dependence. Neuropsychopharmacology. 13(4):1995;301-307.
62. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
63. Trujillo K.A., Akil H. Inhibition of opiate tolerance by non-competitive N-methyl-D-aspartate receptor antagonists. Brain Res. 633:1994;178-188.
64. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies: what advantages do they offer for the control of pain syndromes? Drugs. 55(1):1998;1-4.
65. Williams, S., Pini, A., Evan, G.I., Hunt, S.P., 1989. Molecular events in the spinal cord following sensory stimulation. In: Cervero, F., Bennett, J.G., Headley, M.P. (Eds.), Processing of Sensory Information in the Superficial Dorsal Horn of the Spinal Cord. Plenum, New York, pp. 273-270.
66. Winter C.A., Risley E.A., Nuss G.W. Carrageenan-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. 111:1962;544-547.
67. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.